Deerfield Management Company, L.P. (Series C) An2 Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$7.7 - $18.82 $1.02 Million - $2.49 Million	132,402 Added 22.67%	716,538 $5.55 Million
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $8.76 Million - $9 Million	584,136 New	584,136 $8.8 Million

Others Institutions Holding ANTX

# of Institutions

Shares Held

13.8M

Call Options Held

Put Options Held

Bml Capital Management, LLC Zionsville, IN

5.75M
Shares

$8.05 Million
4.93% of portfolio
Almitas Capital LLC Santa Monica, CA

1.31M
Shares

$1.84 Million
0.87% of portfolio
Vanguard Group Inc Valley Forge, PA

1.04M
Shares

$1.45 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

580K
Shares

$811,682
0.0% of portfolio
Peapod Lane Capital LLC Bedford Hills, NY

579K
Shares

$810,355
0.79% of portfolio

View Full List

About AN2 Therapeutics, Inc.

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $27.2M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

More about ANTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account